Tildrakizumab

From Wikipedia, the free encyclopedia
Tildrakizumab ?
Monoclonal antibody
Source Humanized (from mouse)
Target IL23
Clinical data
Legal status ?
Identifiers
CAS number 1326244-10-3
ATC code None
Chemical data
Formula C6426H9918N1698O2000S46 
Mol. mass 144.4 kDa

Tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[1]

This drug was developed by Merck Sharp & Dohme Corp.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Tildrakizumab, American Medical Association.



This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.